- Home
- AKA vs IPHA Comparison
AKA vs IPHA Comparison
Compare AKA & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKA
- IPHA
- Stock Information
- Founded
- AKA 2018
- IPHA 1999
- Country
- AKA United States
- IPHA France
- Employees
- AKA N/A
- IPHA N/A
- Industry
- AKA Catalog/Specialty Distribution
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- AKA Consumer Discretionary
- IPHA Health Care
- Exchange
- AKA Nasdaq
- IPHA Nasdaq
- Market Cap
- AKA 137.0M
- IPHA 160.1M
- IPO Year
- AKA 2021
- IPHA 2019
- Fundamental
- Price
- AKA $12.20
- IPHA $1.88
- Analyst Decision
- AKA Strong Buy
- IPHA Strong Buy
- Analyst Count
- AKA 4
- IPHA 3
- Target Price
- AKA $25.75
- IPHA $5.00
- AVG Volume (30 Days)
- AKA 14.4K
- IPHA 575.5K
- Earning Date
- AKA 11-05-2025
- IPHA 09-17-2025
- Dividend Yield
- AKA N/A
- IPHA N/A
- EPS Growth
- AKA N/A
- IPHA N/A
- EPS
- AKA N/A
- IPHA N/A
- Revenue
- AKA $595,281,000.00
- IPHA $14,839,695.00
- Revenue This Year
- AKA $7.08
- IPHA $22.29
- Revenue Next Year
- AKA $4.31
- IPHA $43.84
- P/E Ratio
- AKA N/A
- IPHA N/A
- Revenue Growth
- AKA 5.44
- IPHA N/A
- 52 Week Low
- AKA $7.00
- IPHA $1.41
- 52 Week High
- AKA $23.60
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- AKA 54.54
- IPHA 44.87
- Support Level
- AKA $11.52
- IPHA $1.73
- Resistance Level
- AKA $13.49
- IPHA $1.92
- Average True Range (ATR)
- AKA 1.07
- IPHA 0.13
- MACD
- AKA -0.08
- IPHA -0.01
- Stochastic Oscillator
- AKA 67.90
- IPHA 15.83
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.